is tirzepatide a gpl1 Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of | Cardiovascular Diabetology Frontiers | GLP-1/GIP dual agonist

Your provider can resubmit with additional clinical evidence or request expedited review

The potential benefits of tirzepatide may include the following: Significant and sustained weight loss Tirzepatide is a dual GLP-1/GIP receptor agonist that helps significantly reduce body weight by enhancing insulin secretion, lowering glucagon levels, and delaying gastric emptying, which contribute to reduced calorie intake and weight loss

This means that as long as your pen stays sealed and refrigerated properly, you can trust that the medication will maintain its intended clinical strength

Avoid self-adjusting doses

Nausea is typically the most prominent symptom, particularly during dose escalation periods